NULISA Assay Services:
- Ultrasensitive automated proteomic platform enables protein biomarker quantitation into the attomolar (sub-fg/ml) range
- Flexible plexing technology spans single-plex, low-plex, and high-plex formats. From one targeted analyte to hundreds of proteins--in a single ultrasensitive proteomics workflow
Close to 12-log dynamic range quantifies low- and high-abundance proteins in the same run, without dilution optimization or platform-switching
- Low sample-volume requirements allow hundreds of analytes ot be quantified from one small sample, preserving limited or irreplaceable material such as biobanked or longitudinal samples
With 35 years of assay development and manufacturing experience, PBL brings assay strategy shaped by context: our team works from a study's biology and design--target list, concentration range, sample type, timeline--to recommend the right NULISA assay and readout method, or develop a custom NULISA-based immunoassay when an existing doesn't cover the target. Every project is built for the specific study, with scientists guiding selection, design, and interpretation rather than simply processing samples.
Connect with Our Service Scientists
- Dual capture-and-release purification strips non-specifically bound material from the antibody-DNA complex before quantification, eliminating background that limits sensitivity in single-purification immunoassay formats
- Dual eadout options-qPCR for single-plex and low-plex assays, next-generation sequencing for high-plex panels-match turnaround and coverage to study needs
- Absoulte quantification reports validated targets in fg/ml-pg/ml rather than relative signal units, enabling direct comparison across cohorts , sites, and time points
- Sub-10% CV across replicates supports reproducinle, analysis-ready data for longitudinal and multi-site studies
